Karyopharm Therapeutics (NASDAQ:KPTI) held its 2026 annual meeting of stockholders virtually on May 21, with shareholders approving all five proposals presented by the company, according to remarks from President and Chief Executive Officer Richard Paulson.
Paulson, who also serves as a director, chaired the meeting and said the virtual format was designed to provide stockholders with the same rights and opportunities to participate as they would have at an in-person meeting. Mike Mano, Karyopharm’s Chief Legal Officer, served as secretary and inspector of election for the meeting.
Stockholders Approve Director Nominees and Plan Amendments
Karyopharm presented five proposals for shareholder consideration, all of which received preliminary approval, Paulson said after the polls closed.
- Barry E. Greene and Christy J. Oliger were elected as Class I directors to serve until the 2029 annual meeting of stockholders and until their successors are duly elected and qualified, or until their resignation or removal.
- Stockholders approved an amendment to the Karyopharm Therapeutics, Inc. 2022 Equity Incentive Plan, as amended, to increase the number of shares of common stock available for issuance under the plan by 3 million shares.
- Stockholders approved an amendment to the company’s amended and restated 2013 Employee Stock Purchase Plan, as amended, to increase the number of shares of common stock available for issuance under the plan by 1.4 million shares.
- Shareholders approved, on an advisory basis, the compensation of the company’s named executive officers as described in the proxy statement.
- Stockholders ratified the appointment of Ernst & Young LLP as Karyopharm’s independent registered public accounting firm for the fiscal year ended Dec. 31, 2026.
Paulson said the final voting results will be included in a Form 8-K to be filed within four business days after the meeting.
No Stockholder Questions Submitted
Before voting began, Paulson invited stockholders to submit questions related to the proposals through the virtual meeting platform. The operator reported that no questions had been submitted on the proposals. After the formal portion of the meeting was adjourned, Paulson again invited questions from stockholders, subject to the company’s rules of conduct. The operator again stated that there were no questions.
Paulson thanked shareholders for participating in the vote and for their continued support of the company “as we execute on our mission to dramatically improve patients’ lives and defeat cancer.”
Company Issues Forward-Looking Statement Reminder
During the meeting, Paulson also reminded participants that certain remarks about future expectations, plans and prospects for the company constitute forward-looking statements under the Private Securities Litigation Reform Act of 1995. He noted that actual results may differ materially due to factors discussed in the risk factors section of Karyopharm’s most recent quarterly report on Form 10-Q filed with the Securities and Exchange Commission.
The meeting was adjourned after the company determined there was no further business and no stockholder questions to address.
About Karyopharm Therapeutics (NASDAQ:KPTI)
Karyopharm Therapeutics (NASDAQ: KPTI) is a clinical-stage biopharmaceutical company focused on discovering and developing novel first-in-class drugs that target the nuclear export protein XPO1. The company’s lead product, selinexor (marketed as XPOVIO), is an oral selective inhibitor of nuclear export (SINE) compound approved for treatment of multiple myeloma and diffuse large B-cell lymphoma. In addition to selinexor, Karyopharm’s pipeline includes second-generation SINE compounds and combination studies in solid tumors and hematologic malignancies.
Founded in 2008 and headquartered in Newton, Massachusetts, Karyopharm has built a research platform around modulation of nuclear export pathways.
